Department of Radiology, Huadu Distinct People's Hospital of Guangzhou, Guangzhou, PR China.
Department of Radiology, China-Japan Union Hospital of Jilin University, ChangChun, PR China.
Acta Radiol. 2022 Aug;63(8):1077-1085. doi: 10.1177/02841851211030768. Epub 2021 Jul 11.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a non-invasive technique which could monitor tumor morphology, blood vessel dynamics, and micro-environmental changes.
To evaluate the value of DCE-MRI semi-quantitative parameters in monitoring the neoadjuvant chemotherapy (NAC) response of osteosarcoma.
Twenty-five patients pathologically confirmed as osteosarcoma received four cycles of NAC followed by surgery. All patients underwent conventional and dynamic MRI twice, before starting chemotherapy and before surgical treatment. With a reference standard of histological response (tumor necrosis rate), semi-quantitative parameters were compared between good response group (TNR ≥ 90%) and non-response group (TNR < 90%). The differences between intra- and inter-group parameters before and after NAC were analyzed by Mann-Whitney U test. Receiver operating characteristic (ROC) analysis was generated to assess the parameters' efficacy in predicting the outcome of NAC.
The changes were statistically significant on slope, maximum signal intensity (SI), time to peak (TTP), signal enhanced extent (SEE), peak percent enhancement (PPE), washout rate (WOR), and enhancement rate (ER) in the good response group ( < 0.05), while only SI and SEE were different in the non-response group after NAC. The changes in Slope, SI, TTP, SEE, WOR, and ER were markedly different ( < 0.05) between the two groups after NAC. Also, at the threshold values of 3.2%/s, 175 s, and 5.4% (slope, TTP, and ER), the sensitivity and specificity for predicting good response to chemotherapy were 83.3% and 92.3%, 91.7% and 69.2%, 84.6% and 75.0%, respectively.
Slope, TTP, and ER values could be used to evaluate and predict the response to NAC in osteosarcoma.
动态对比增强磁共振成像(DCE-MRI)是一种非侵入性技术,可监测肿瘤形态、血管动力学和微环境变化。
评估 DCE-MRI 半定量参数在监测骨肉瘤新辅助化疗(NAC)反应中的价值。
25 例经病理证实为骨肉瘤的患者接受了 4 个周期的 NAC 治疗,然后进行手术。所有患者在开始化疗前和手术治疗前均接受了两次常规和动态 MRI 检查。以组织学反应(肿瘤坏死率)为参考标准,比较了 NAC 后良好反应组(TNR≥90%)和无反应组(TNR<90%)之间的半定量参数。采用 Mann-Whitney U 检验分析 NAC 前后组内和组间参数的差异。生成受试者工作特征(ROC)分析以评估参数在预测 NAC 结果方面的效果。
在良好反应组中,斜率、最大信号强度(SI)、达峰时间(TTP)、信号增强程度(SEE)、峰值增强百分比(PPE)、洗脱率(WOR)和增强率(ER)的变化具有统计学意义( <0.05),而 NAC 后无反应组仅 SI 和 SEE 不同。NAC 后,两组间斜率、SI、TTP、SEE、WOR 和 ER 的变化差异显著( <0.05)。此外,在斜率、TTP 和 ER 的阈值分别为 3.2%/s、175 s 和 5.4%时,预测化疗良好反应的敏感性和特异性分别为 83.3%和 92.3%、91.7%和 69.2%、84.6%和 75.0%。
斜率、TTP 和 ER 值可用于评估和预测骨肉瘤对 NAC 的反应。